

Vunakizumab

| | |
|-----------|---|
| Cat. No.: | HY-P99335 |
| CAS No.: | 1792181-33-9 |
| Target: | Interleukin Related |
| Pathway: | Immunology/Inflammation |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

Description

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgG_k monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis^[1].

REFERENCES

[1]. Chunlei Zhang, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. *J Am Acad Dermatol.* 2022 Jul;87(1):95-102.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA